Frank I. Scott, MD, MSCE, is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Colorado Anschutz Medical Campus. He is an expert in inflammatory bowel disease, with a particular interest in the risk-benefit balance of biologic and immunosuppressive therapies in Crohn's disease and ulcerative colitis. Dr. Scott received his undergraduate degree from the University of Pennsylvania and medical degree from Temple University in Philadelphia. After completing his internal medicine residency at Weill Cornell Medical Center, Dr. Scott returned to Philadelphia for his gastroenterology fellowship at the University of Pennsylvania, also completing an advanced fellowship in inflammatory bowel diseases in 2013 as well as a Masters' of Science in Clinical Epidemiology (MSCE). After several years on faculty at the University of Pennsylvania, Dr. Scott joined the faculty at the University of Colorado in 2016.
Dr. Scott's research interests include using both quantitative and qualitative methods to better understand the risk benefit balance and medication positioning in IBD and how to best optimize the use of current therapies while reducing delays in care. He has significant experience in epidemiologic methods including decision analyses, Markov modeling, cost-effectiveness analysis, study design using large secondary and EMR-derived data, and disease risk and propensity score adjustment in such data. He serves as Co-Director for IBD Qorus, the Crohn's and Colitis Foundation's premier quality improvement network, and also serves on the American Gastroenterological Association's Clinical Guidelines Committee.